RDHL: RedHill Biopharma Ltd Company Short-Term Debt

Symbol and logo of brand RedHill Biopharma Ltd (RDHL)

The current RedHill Biopharma (RDHL) share price chart on the GURU.Markets platform demonstrates the asset's dynamics, with its metric currently at 0.00. The business focuses on the commercialization of certified gastrointestinal treatments and the testing of new antiviral formulas. Demand for healthcare remains stable and independent of economic cycles, although success depends on clinical trial outcomes. Revenue is based on the supply of proprietary drugs through insurance systems.

RDHL (redhillbio.com) Company Short-Term Debts history from 07/04/2022 to 11/01/2026

Analytical breakdowns for RedHill Biopharma

- current quotes and average value forecast:
Price Chart RedHill|RDHL - Fair Value Consensus
- market capitalization information:
Market Value RedHill Biopharma Ltd.|RDHL - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share RedHill Biopharma|RDHL - Book Capitalization|Market Cap to Net Assets Ratio redhillbio.com|RDHL - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital RedHill Biopharma|RDHL - Long-Term Indebtedness to Equity|Short-Term Debt to Capital RedHill|RDHL - Company Total Debt Obligations|Debt to Book Value RedHill Biopharma Ltd.|RDHL - Amount of Long-Term Liabilities|Company Short-Term Debt RedHill Biopharma|Quick Ratio redhillbio.com
- net income and valuation multiples indicators:
RDHL - Company Net Income
Fundamental company analysis:redhillbio.com - RDHL
Manufactured products of RedHill Biopharma Ltd

The development of the RedHill Biopharma (RDHL) precision therapy ecosystem requires precise working capital management to support unique treatment protocols. The assessment of short-term debt reflects obligations maturing within one year, where a decrease in the amount confirms rising liquidity, while excessive reduction may limit operational flexibility, impacting the company's overall financial stability and market value.

Who RedHill Biopharma competes with

PHAT - Company Short-Term Debt|Company Short-Term Loans and Borrowings TERN (Terns Pharma)|ironwoodpharma.com (IRWD) - Company Short-Term Debt|Company Current Liabilities Curanex Pharmaceuticals|IMRN (Immuron Ltd) - Company Short-Term Debts|Company Short-Term Debts evokepharma.com|Company Current Liabilities ENTO (Entero Therapeutics, Inc.)|PALI (palisadebio.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts JAGX (Jaguar Animal Health)|Short-Term Indebtedness Biora Therapeutics, Inc|Morphic Holding, Inc. - Company Short-Term Debts